Karessa – new research and development area
Karessa Pharma Holding AB (Publ) has received an exclusive license from Uppsalagruppen Medical AB for development of preparations within the benzodiazepine group based on the patented transbuccal drug delivery platform. The objective is with limited contributions develop a prioritized product including preclinical phase, thereafter, finalizing agreements with partners for further development. This means the company will expand to further development area except erectile dysfunction.
Karessa Pharma announces today that the company's license has been reinforced through patent granted in Europe
The European Patent Office (EPO) has issued a granted patent regarding patent application for the use and formulation of buccal films based on alginate. The grant of the patent with number 1976562 will be published by EPO's European Patent Bulletin on 21st of February 2018.
Karessa Pharma Holding AB announces today that a patent application for Vardenafil buccal film has been submitted to the European Patent Office
On the 20th of December 2017, Karessa submitted an application to the European Patent Office concerning the use and formulation of buccal film with Vardenafil.
Karessa Pharma Holding AB announces today that the last patient is dosed in the company's clinical study with K-03 Vardenafil buccal film
The final dose of healthy volunteers in Karessa's clinical trial with K-03/1 buccal film is now performed and the study will be completed as planned today, the 15th of December 2017.
Karessa Pharma Holding AB announces today that the first patient is dosed in the company's clinical study with K-03 Vardenafil buccal film
Today, the dosing of healthy volunteers begins in Karessa's clinical trial K-03/1 buccal film. The study will last for five weeks and is planned to be completed on 15th of December 2017.
Karessa Pharma Holding AB announces today that they have been approved by the MPA to start a clinical study with K-03 Vardenafil buccal film
Karessa submitted an application to the Swedish Medical Products Agency on 31st of August to perform a Phase I study on healthy volunteers of male subjects. Today, the Medical Products Agency announced that they approved the application.
Update and status of Karessa Pharma's project K-03
Karessa Pharma Holding AB is working actively to operate the most advanced project, K-03 Vardenafil buccal film, through its various development phases as effectively as possible.
Leading executives in Karessa Pharma AB acquire stock options in Karessa Pharma Holding AB
Karessa Pharma Holding AB announces today that the stock option program adopted at the Annual General Meeting on 29th of May 2017 has now been implemented. Of the total of 330,000 options in Karessa Incentive AB, 280,000 have been allocated to leading executives.
Karessa has today submitted an application for clinical trial for project K-03 to the Medical Products Agency
Karessa Pharma Holdning AB announces today that an application for a clinical trial with Vardenafil within the project K-03 has been submitted to the Swedish Medical Products Agency.
Bulletin from Annual General Meeting in Karessa Pharma Holding AB (publ) on the 29th of May 2017
At Karessa Pharma Holding AB (publ)'s Annual General Meeting on May 29th 2017, all members of the Board of Directors and the Chairman of the Board were re-elected. The Annual General Meeting approved a directed issue of stock options.
Karessa has signed an agreement with PCG Clinical Services AB for performance of a clinical study within the project K-03
Karessa Pharma Holding AB announces today that an agreement between Karessa and PCG Clinical Services AB has been signed for the performance of a first human study within the project K-03.
Notice of Annual General Meeting 2017 in Karessa Pharma Holding AB (publ)
The shareholders of Karessa Pharma Holding AB (publ) are hereby invited to participate in the Annual General Meeting to be held on May 29, 2017 at 2 p.m. at Advokatfirman Lindberg & Saxon's office, Cardellgatan 1, Stockholm, Sweden.
Karessa has signed an agreement for manufacturing of clinical trial material for the project K-03
Karessa Pharma Holding AB announces today that an agreement for manufacture of clinical trial material has been signed between Karessa and Recipharm. The intention is to manufacture clinical trial material that will be used for Proof of Concept studies later this year.
Karessa announces that the plan for the two projects K-01 and K-03 remains unchanged
Karessa Pharma Holding AB announces today that the plan presented in December about the development of K-01 and K-03 remains until further notice.
Bulletin from Extraordinary General Meeting in Karessa Pharma Holding AB (publ) on the 3rd of March 2017
At the Extraordinary General Meeting of Karessa Pharma Holding AB (publ) on March 3rd 2017, Ulf Lindberg was elected to the Board of Directors as new Chairman of the Board and Michael Brobjer was elected as new Board member. Michael Brobjer also takes over as CEO.
New Board members and new Chairman of the Board are proposed in Karessa Pharma Holding AB (publ)
Ulf Lindberg is proposed as new Chairman of the Board and incoming CEO, Michael Brobjer, is proposed as new Board member of Karessa Pharma Holding AB (publ).
Karessa changes its development strategy to facilitate the commercialization of new pharmaceuticals for impotence
Karessa Pharma AB announces today that the company has decided that the next step for the drug candidates K-01 and K-03 is to perform Proof of Concept clinical studies before pivotal studies for the projects. This is considered to facilitate the process of finding suitable commercial partners for future market launches. Because of the changed strategy, the company will present a revised overall development and registration plan for the projects concerned in the first quarter of 2017.
Karessa starts new pharmaceutical project with the opportunity to reach clinical phase during 2017 and re-prioritize the project portfolio
Karessa Pharma AB announces today that the company initiated a new pharmaceutical project, K-03, based on the approved and well proven drug molecule Vardenafil. Vardenafil is the active substance in the impotence drug Levitra, whose patent expires in 2018. The sale of Levitra, marketed as Staxyn in the United States, amounted to approximately SEK 2.1 billion in 2015. Based on new promising research results and the possibility to start clinical trials with K-03 already in 2017, a down-prioritization of the company's preclinical project K-02 is being made.
Karessa Pharma signs cooperation agreement with PlastoPharma for the manufacturing of the drug candidate Vigressa™
Karessa Pharma announces today that the company has signed a cooperation agreement with Laboratories Plasto Santé (PlastoPharma) regarding the manufacturing of pharmaceuticals for the upcoming clinical trial of Vigressa™ - a drug candidate with potential to improve the treatment of impotence. The collaboration with PlastoPharma is also aimed to ensuring a well-functioning and cost-effective manufacturing of Vigressa™ on a commercial scale for future market launch.
Karessa Pharma in final negotiations with manufacturing company regarding start of manufacturing of the drug candidate Vigressa™
Karessa Pharma announces today that the company has entered into final negotiations with Laboratories Plasto Santé (PlastoPharma) regarding the manufacturing of pharmaceuticals for the upcoming clinical trial of Vigressa™ - a drug candidate with the potential to improve the treatment of impotence. The ambition for the cooperation with PlastoPharma is also to ensure a well-functioning and cost-effective manufacturing of Vigressa™ on a commercial scale for future market launch.
Karessa starts collaboration with Pharma Consulting Group for upcoming pivotal clinical programmme
Karessa has entered into a cooperation agreement with the contract research company Pharma Consulting Group. The agreement gives Karessa access to a well-reputed partner in the ongoing work to develop next-generation pharmaceuticals to treat erectile dysfunction.
Karessa intensifies the development work to prepare for clinical trials within erectile dysfunction
Karessa intensifies the work of developing its unique and patented drug delivery platform This, among other things, by expanding and streamlining the laboratory in Stockholm, where capacity is increased and new analytical equipment is being installed. These measures are important steps in the process of streamlining the final phase of the development and formulation work of the two pharmaceutical projects in Karessa's portfolio.
Karessa's licence reinforced through patent granted in South Korea
A recently granted patent in South Korea has reinforced Karessa's licence in the field of erectile dysfunction. This entails recognition of Karessa's technical platform as well as sole rights to the company's products on the large and growing South Korean market.
Karessa's first day of trading on First North
Today is the first trading day for Karessa (ticker code KARE) on Nasdaq Stockholm First North. Karessa is developing and commercialising the next generation of pharmaceutical products to treat erectile dysfunction. The market is worth around USD 4.3 billion and is about to undergo significant changes, opening up major opportunities for Karessa.
Stefan Arver joins the Board of Karessa Pharma
Stefan Arver, a prominent fellow, chief physician and section manager at the Karolinska University Hospital, has been appointed a new member of Karessa's Board of Directors. His recruitment further strengthens the company's expertise in the field of male sexual health.
Karessa Pharma on Nasdaq Stockholm First North
Karessa Pharma Holding AB has been approved for listing on Nasdaq Stockholm First North. The first trading day will be on the 10th of February. A complete company description can be downloaded from www.karessa.se (http://karessa.se/en/home/).